SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Lab gains on settling litigation concerning Texas Medicaid Program

16 Oct 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 601.75, up by 3.70 points or 0.62% from its previous closing of Rs. 598.05 on the BSE.

The scrip opened at Rs. 598.00 and has touched a high and low of Rs. 604.50 and Rs. 596.25 respectively. So far 17450 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 667.30 on 03-Sep-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.

Last one week high and low of the scrip stood at Rs. 619.00 and Rs. 591.00 respectively. The current market cap of the company is Rs. 25499.85 crore.

The promoters holding in the company stood at 63.37% while Institutions and Non-Institutions held 21.49% and 13.73% respectively.

Ranbaxy Laboratories has settled the litigation concerning its participation in the Texas Medicaid Program. Under the settlement agreement, the pharma major will make payments to the State of Texas totaling $39.75 million in a series of tranches through August 2015. The company has settled the matter to avoid any further distraction and uncertainty of continued litigation with the state of Texas.

The claims at issue related exclusively to the manner in which the Ranbaxy has historically reported pricing data to Texas Medicaid for certain of its drugs. As has been widely reported, the State of Texas has brought nearly identical claims against virtually every other major pharmaceutical manufacturer in the United States.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1653.80
Dr. Reddys Lab 1215.95
Cipla 1228.20
Zydus Lifesciences 927.75
Lupin 2307.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×